Cadrenal Therapeutics
PONTE VEDRA, FL, Spain · Biotechnology · 4 employees
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths
Funding history
- Venture - Series Unknown — $8.8M — Jul 2026
- Series C — $7.9M — Apr 2026
- Venture - Series Unknown — $4.4M — Dec 2025
- Venture - Series Unknown — $9.4M — Nov 2024
- Venture - Series Unknown — $7.5M — Jul 2023
Recent signals
- Jul 15, 2026: Raised $8.8M in Venture - Series Unknown
- Apr 06, 2026: Raised $7.9M in Series C
- Feb 24, 2026: SEC 8-K (8.01): On February 24, 2026, Cadrenal Therapeutics, Inc. announced via press release the outcomes of a Phase 2 trial for CAD-1005, aimed at addressing heparin-induced thrombocytopenia (HIT). This trial, which was randomized, blinded, and placebo-controlled, focused on the safety and efficacy of CAD-1005, a selective inhibitor of 12-lipoxygenase, in patients under standard anticoagulant therapy. The primary endpoint of the trial was the platelet count recovery rate; however, it did not meet this endpoint, highlighting challenges in the development of treatments for this critical condition. This event carries strategic implications for Cadrenal Therapeutics as it impacts their drug development pipeline and future therapeutic approaches for patients affected by HIT.
- Dec 31, 2025: Raised $4.4M in Venture - Series Unknown
- Nov 18, 2025: SEC 8-K (1.01): On November 18, 2025, Cadrenal Therapeutics, Inc. filed a prospectus supplement in connection with their 'at the market offering' program, allowing for the sale of up to $3,438,062 of shares of their common stock through H.C. Wainwright & Co., LLC. This follows the existing At the Market Offering Agreement dated March 11, 2024. To date, the company has successfully sold a total of $9,386,964 under this agreement. The action indicates an ongoing effort to raise capital through equity financing, which may enhance the company’s liquidity position and support operational objectives.
- Mar 13, 2025: Cadrenal Therapeutics Secures Collaboration Agreement with Abbott for TECH-LVAD Trial
- Nov 14, 2024: Raised $9.4M in Venture - Series Unknown
- Oct 23, 2024: Cadrenal Therapeutics Joins Corporate Council of Anticoagulation Forum
See plans & pricing → Track Cadrenal Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.